Fate Therapeutics (FATE) Set to Announce Earnings on Monday
Fate Therapeutics (NASDAQ:FATE) is scheduled to announce its earnings results after the market closes on Monday, March 5th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.
Fate Therapeutics (NASDAQ:FATE) opened at $13.27 on Friday. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $676.53, a P/E ratio of -13.97 and a beta of 1.65. Fate Therapeutics has a 52-week low of $2.52 and a 52-week high of $14.03.
FATE has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Friday, November 10th. ValuEngine downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Raymond James Financial restated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, December 12th. Piper Jaffray Companies initiated coverage on Fate Therapeutics in a research report on Monday, December 18th. They issued an “overweight” rating and a $10.00 target price for the company. Finally, Wedbush restated an “outperform” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Monday, December 18th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Fate Therapeutics presently has an average rating of “Buy” and a consensus target price of $7.71.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.